Clinical Monitoring White Papers & Case Studies
-
Pharmacovigilance Monitoring Services
1/18/2012
Norwich Clinical Services offers comprehensive pharmacovigilance services for pre-marketing product safety, post-marketing surveillance and data analysis.
-
Epilepsy Drug Study: Ambulatory EEG Application For Safety And Efficacy
1/9/2012
A global leader dedicated to the development and commercialization of pharmaceuticals to treat serious neurological and psychiatric disorders.
-
Pharmaceutical Trials Employing POCT
11/23/2011
The following is a partial listing of clinical trials performed to establish efficacy of novel pharmaceuticals that have employed point-of-care testing (POCT) as an integral part of the protocol. Many additional studies have employed POCT, either as a required portion of the protocol, or as an option for specific diagnostic assays. However, many of these trials do not specifically call out the use of POCT in the final publication.
-
Trends In Clinical Practice: Growth Of POCT
11/23/2011
Point-of-Care Testing (POCT) is most frequently defined as “clinical laboratory testing conducted close to the site of patient care, typically by clinical personnel whose primary training is not in the clinical laboratory sciences.
-
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study For Evaluation Of Efficacy And Safety Of Study Drug Versus Warfarin In Subjects With Atrial Fibrillation
11/23/2011
Atrial fibrillation (AF) is the most common type of arrhythmia in adults and becomes more common with increased age.
-
Human ADME & Studies With Radiolabeled Compounds
During clinical drug development there can be several situations where the use of radiolabeled medication or other radiolabeled compounds is required or favorable to accomplish the study objectives. This whitepaper is mainly focusing on human ADME studies and “microdose” studies to assess absolute bioavailability (BA). The major part of the information in this overview is also relevant for other clinical studies with a radiolabeled compound. By Ad Roffel and Henk Poelman, PRA Health Sciences
This website uses cookies to ensure you get the best experience on our website. Learn more